Arca Biopharma (ABIO) 1.60 $ABIO
ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation
Business Wire - Thu Apr 17, 7:30AM CDT
--Atrial Fibrillation Estimated Global Prevalence of 33.5 Million Patients in 2010
ARCA biopharma Files Shelf Registration Statement
Business Wire - Fri Apr 04, 3:05PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, depository shares, debt securities and/or warrants in one or more offerings. As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement and the Company is not required to offer the securities in the future pursuant to the registration statement.
ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio
Marketwire - Wed Mar 19, 6:05AM CDT
ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Michael R. Bristow, president and CEO, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Any interested parties may tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Top Gainers Technical Data: Ocean Power Technologies, ARCA Biopharma, Ubiquiti Networks, and Pinnacle Entertainment
PR Newswire - Wed Mar 12, 8:24AM CDT
Editor Note: For more information about this release, please scroll to bottom.
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dan Mitchell Joins ARCA biopharma Board of Directors
Business Wire - Wed Feb 12, 8:15AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to the Company's Board of Directors. He will serve on the Audit and Nominating and Corporate Governance Committees of the Board of Directors.
LIN Media LLC Announces Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Feb 06, 6:30AM CST
LIN Media LLC ("LIN Media" or the "Company"; NYSE: LIN), a local multimedia company, today reported results for its fourth quarter and full year ended December 31, 2013.
5 Stocks Insiders Love Right Now
at The Street - Wed Feb 05, 11:42AM CST
Insiders at these companies have been scooping up shares of their own companies lately.
ARCA biopharma Announces Pricing of $9 Million Public Offering of Common Stock and Warrants
Business Wire - Tue Feb 04, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has priced its previously announced public offering of common stock and warrants at a price of $1.70 for each share of common stock and a related warrant to purchase 0.25 shares of common stock, for gross proceeds of $8.7 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company. The purchase price represents a 9.6% discount to the closing price of the Company's common stock on the Nasdaq Capital Market on February 3, 2014. The warrants are immediately exercisable, have a term of 5 years and an exercise price of $2.125 per share. The offering is expected to close on or about February 7, 2014, subject to the satisfaction of customary closing conditions.
ARCA Biopharma plans to offer common stock and warrants to the public
M2 - Tue Feb 04, 5:45AM CST
US-based biopharmaceutical company ARCA Biopharma Inc (NasdaqCM:ABIO) said on Monday that it proposes to offer and sell common stock and warrants in a public offering.
ARCA biopharma Announces Proposed Public Offering of Common Stock and Warrants
Business Wire - Mon Feb 03, 3:05PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it intends to offer and sell common stock and warrants in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC) and declared effective on April 4, 2011 (Registration No. 333-172686). The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital and operational purposes.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ARCA Biopharma Up 33.3%, Shares Break Through Resistance (ABIO)
Comtex SmarTrend(R) - Wed Jan 08, 10:12AM CST
ARCA Biopharma (NASDAQ:ABIO) is one of today's best performing low-priced stocks, up 33.3% to $2.40 on 7.0x average daily volume. Thus far today, ARCA Biopharma has traded 11.1 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (33.3% to the Dow's -0.4%) and outperformed the S&P 500 (33.3% to the S&P's 0.0%) during today's trading.
ARCA biopharma Announces US FDA Acceptance of Gencaro Companion Diagnostic Test IDE
Business Wire - Wed Jan 08, 7:29AM CST
--Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ARCA biopharma to Present at Biotech Showcase 2014
Business Wire - Tue Jan 07, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January 13-15, 2014 in San Francisco, California.
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma
PR Newswire - Mon Dec 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), ARCA biopharma, Inc. (NASDAQ: ABIO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma
at The Street - Fri Dec 06, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Stocks Outperformed the Broader Markets: Facebook Inc, Twitter Inc, CF Industries Holdings, Green Mountain Coffee Roasters, Arca Biopharma
PR Newswire - Thu Dec 05, 8:18AM CST
Market Buzz Report, which scans live penny stocks update, issues interesting stock analysis for CF Industries Holdings, Inc.(NYSE:CF), Facebook Inc (NASDAQ:FB), Twitter Inc (NYSE:TWTR), Green Mountain Coffee Roasters Inc.(NASDAQ:GMCR), Arca Biopharma Inc (NASDAQ:ABIO).
ARCA biopharma Announces IDE Submission to US FDA for Gencaro Companion Diagnostic Test
Business Wire - Thu Dec 05, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp(R)) (NYSE: LH) has informed ARCA that LabCorp has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for the planned companion diagnostic test for Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). If accepted by the FDA, the IDE will allow the companion diagnostic test to be used in the planned GENETIC-AF clinical trial. ARCA's Gencaro Investigational New Drug (IND) application for AF has been accepted by the U.S. Food and Drug Administration (FDA) and is active.
ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation
Business Wire - Thu Apr 17, 7:30AM CDT
--Atrial Fibrillation Estimated Global Prevalence of 33.5 Million Patients in 2010
ARCA biopharma Files Shelf Registration Statement
Business Wire - Fri Apr 04, 3:05PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, depository shares, debt securities and/or warrants in one or more offerings. As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement and the Company is not required to offer the securities in the future pursuant to the registration statement.
ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio
Marketwire - Wed Mar 19, 6:05AM CDT
ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Michael R. Bristow, president and CEO, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Any interested parties may tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
Top Gainers Technical Data: Ocean Power Technologies, ARCA Biopharma, Ubiquiti Networks, and Pinnacle Entertainment
PR Newswire - Wed Mar 12, 8:24AM CDT
Editor Note: For more information about this release, please scroll to bottom.
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dan Mitchell Joins ARCA biopharma Board of Directors
Business Wire - Wed Feb 12, 8:15AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to the Company's Board of Directors. He will serve on the Audit and Nominating and Corporate Governance Committees of the Board of Directors.
LIN Media LLC Announces Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Feb 06, 6:30AM CST
LIN Media LLC ("LIN Media" or the "Company"; NYSE: LIN), a local multimedia company, today reported results for its fourth quarter and full year ended December 31, 2013.
5 Stocks Insiders Love Right Now
at The Street - Wed Feb 05, 11:42AM CST
Insiders at these companies have been scooping up shares of their own companies lately.
ARCA biopharma Announces Pricing of $9 Million Public Offering of Common Stock and Warrants
Business Wire - Tue Feb 04, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has priced its previously announced public offering of common stock and warrants at a price of $1.70 for each share of common stock and a related warrant to purchase 0.25 shares of common stock, for gross proceeds of $8.7 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company. The purchase price represents a 9.6% discount to the closing price of the Company's common stock on the Nasdaq Capital Market on February 3, 2014. The warrants are immediately exercisable, have a term of 5 years and an exercise price of $2.125 per share. The offering is expected to close on or about February 7, 2014, subject to the satisfaction of customary closing conditions.
ARCA Biopharma plans to offer common stock and warrants to the public
M2 - Tue Feb 04, 5:45AM CST
US-based biopharmaceutical company ARCA Biopharma Inc (NasdaqCM:ABIO) said on Monday that it proposes to offer and sell common stock and warrants in a public offering.
ARCA biopharma Announces Proposed Public Offering of Common Stock and Warrants
Business Wire - Mon Feb 03, 3:05PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it intends to offer and sell common stock and warrants in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC) and declared effective on April 4, 2011 (Registration No. 333-172686). The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital and operational purposes.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ARCA Biopharma Up 33.3%, Shares Break Through Resistance (ABIO)
Comtex SmarTrend(R) - Wed Jan 08, 10:12AM CST
ARCA Biopharma (NASDAQ:ABIO) is one of today's best performing low-priced stocks, up 33.3% to $2.40 on 7.0x average daily volume. Thus far today, ARCA Biopharma has traded 11.1 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (33.3% to the Dow's -0.4%) and outperformed the S&P 500 (33.3% to the S&P's 0.0%) during today's trading.
ARCA biopharma Announces US FDA Acceptance of Gencaro Companion Diagnostic Test IDE
Business Wire - Wed Jan 08, 7:29AM CST
--Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ARCA biopharma to Present at Biotech Showcase 2014
Business Wire - Tue Jan 07, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January 13-15, 2014 in San Francisco, California.
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma
PR Newswire - Mon Dec 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), ARCA biopharma, Inc. (NASDAQ: ABIO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma
at The Street - Fri Dec 06, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Stocks Outperformed the Broader Markets: Facebook Inc, Twitter Inc, CF Industries Holdings, Green Mountain Coffee Roasters, Arca Biopharma
PR Newswire - Thu Dec 05, 8:18AM CST
Market Buzz Report, which scans live penny stocks update, issues interesting stock analysis for CF Industries Holdings, Inc.(NYSE:CF), Facebook Inc (NASDAQ:FB), Twitter Inc (NYSE:TWTR), Green Mountain Coffee Roasters Inc.(NASDAQ:GMCR), Arca Biopharma Inc (NASDAQ:ABIO).
ARCA biopharma Announces IDE Submission to US FDA for Gencaro Companion Diagnostic Test
Business Wire - Thu Dec 05, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp(R)) (NYSE: LH) has informed ARCA that LabCorp has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for the planned companion diagnostic test for Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). If accepted by the FDA, the IDE will allow the companion diagnostic test to be used in the planned GENETIC-AF clinical trial. ARCA's Gencaro Investigational New Drug (IND) application for AF has been accepted by the U.S. Food and Drug Administration (FDA) and is active.
